Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.
Amyloid
/ metabolism
Animals
Brain
/ metabolism
Cells, Cultured
Humans
Mice, Inbred C57BL
Mice, Transgenic
Models, Animal
Multiple System Atrophy
/ metabolism
Myelin Basic Protein
/ metabolism
Myelin Proteolipid Protein
/ genetics
Neurons
/ metabolism
Oligodendroglia
/ metabolism
Parkinson Disease
/ pathology
Phosphorylation
Phosphoserine
/ metabolism
Promoter Regions, Genetic
/ genetics
Protein Aggregates
Protein Multimerization
alpha-Synuclein
/ metabolism
GCIs
multiple system atrophy
α-synuclein
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
29 10 2020
29 10 2020
Historique:
received:
30
06
2020
revised:
20
10
2020
accepted:
26
10
2020
entrez:
3
11
2020
pubmed:
4
11
2020
medline:
22
6
2021
Statut:
epublish
Résumé
The synucleinopathy underlying multiple system atrophy (MSA) is characterized by the presence of abundant amyloid inclusions containing fibrillar α-synuclein (α-syn) aggregates in the brains of the patients and is associated with an extensive neurodegeneration. In contrast to Parkinson's disease (PD) where the pathological α-syn aggregates are almost exclusively neuronal, the α-syn inclusions in MSA are principally observed in oligodendrocytes (OLs) where they form glial cytoplasmic inclusions (GCIs). This is intriguing because differentiated OLs express low levels of α-syn, yet pathogenic amyloid α-syn seeds require significant amounts of α-syn monomers to feed their fibrillar growth and to eventually cause the buildup of cytopathological inclusions. One of the transgenic mouse models of this disease is based on the targeted overexpression of human α-syn in OLs using the PLP promoter. In these mice, the histopathological images showing a rapid emergence of S129-phosphorylated α-syn inside OLs are considered as equivalent to GCIs. Instead, we report here that they correspond to the accumulation of phosphorylated α-syn monomers/oligomers and not to the appearance of the distinctive fibrillar α-syn aggregates that are present in the brains of MSA or PD patients. In spite of a propensity to co-sediment with myelin sheath contaminants, the phosphorylated forms found in the brains of the transgenic animals are soluble (>80%). In clear contrast, the phosphorylated species present in the brains of MSA and PD patients are insoluble fibrils (>95%). Using primary cultures of OLs from PLP-αSyn mice we observed a variable association of S129-phosphorylated α-syn with the cytoplasmic compartment, the nucleus and with membrane domains suggesting that OLs functionally accommodate the phospho-α-syn deriving from experimental overexpression. Yet and while not taking place spontaneously, fibrillization can be seeded in these primary cultures by challenging the OLs with α-syn preformed fibrils (PFFs). This indicates that a targeted overexpression of α-syn does not model GCIs in mice but that it can provide a basis for seeding aggregation using PFFs. This approach could help establishing a link between α-syn aggregation and the development of a clinical phenotype in these transgenic animals.
Identifiants
pubmed: 33138150
pii: cells9112371
doi: 10.3390/cells9112371
pmc: PMC7693764
pii:
doi:
Substances chimiques
Amyloid
0
Myelin Basic Protein
0
Myelin Proteolipid Protein
0
Protein Aggregates
0
alpha-Synuclein
0
Phosphoserine
17885-08-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Neurodegener. 2017 Jul 4;12(1):52
pubmed: 28676095
J Neurol Sci. 1989 Dec;94(1-3):79-100
pubmed: 2559165
Mov Disord. 2020 Jul;35(7):1163-1172
pubmed: 32291831
J Cell Sci. 2013 Jan 15;126(Pt 2):696-704
pubmed: 23203798
Glia. 2014 Jun;62(6):964-70
pubmed: 24590631
PLoS Pathog. 2013;9(10):e1003702
pubmed: 24130496
Am J Pathol. 2005 Mar;166(3):869-76
pubmed: 15743798
Brain. 2020 Jun 1;143(6):1780-1797
pubmed: 32428221
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9593-8
pubmed: 27482103
Acta Neuropathol. 2019 Mar;137(3):455-466
pubmed: 30721406
Acta Neuropathol Commun. 2018 Jan 3;6(1):2
pubmed: 29298733
Neuron. 2005 Mar 24;45(6):847-59
pubmed: 15797547
Mov Disord. 2019 Nov;34(11):1629-1642
pubmed: 31692132
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Sci Adv. 2020 Oct 2;6(40):
pubmed: 33008896
EMBO Rep. 2002 Jun;3(6):583-8
pubmed: 12034752
Mov Disord. 2014 Mar;29(3):388-95
pubmed: 24442757
Neurobiol Dis. 2020 Jul;141:104876
pubmed: 32339655
Glia. 2014 Mar;62(3):387-98
pubmed: 24382629
Neurosci Lett. 1998 Jun 19;249(2-3):180-2
pubmed: 9682846
Mov Disord. 2019 Feb;34(2):255-263
pubmed: 30452793
Synapse. 2014 Mar;68(3):98-106
pubmed: 24243499
Am J Pathol. 2007 Oct;171(4):1291-303
pubmed: 17823288
J Neurosci. 2005 Nov 16;25(46):10689-99
pubmed: 16291942
Brain. 2017 May 1;140(5):1420-1436
pubmed: 28334990
Exp Neurol. 2010 Aug;224(2):459-64
pubmed: 20493840
Exp Neurol. 2013 Sep;247:531-6
pubmed: 23399889
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
J Neurochem. 2019 Sep;150(5):612-625
pubmed: 31055836
J Neuropathol Exp Neurol. 2019 Oct 1;78(10):877-890
pubmed: 31504665
Nat Neurosci. 2019 Jan;22(1):65-77
pubmed: 30559480
Mov Disord. 2013 Mar;28(3):347-55
pubmed: 23426727
Brain. 1994 Apr;117 ( Pt 2):235-43
pubmed: 8186951
J Mol Biol. 2007 Mar 9;366(5):1510-22
pubmed: 17222866
Acta Neuropathol. 2019 Sep;138(3):415-441
pubmed: 31011860
Nature. 2020 Sep;585(7825):464-469
pubmed: 32461689
Neurosci Lett. 1998 Jul 31;251(3):205-8
pubmed: 9726379
Stem Cell Reports. 2015 Aug 11;5(2):174-84
pubmed: 26235891
Acta Neuropathol Commun. 2016 Feb 09;4:12
pubmed: 26860328
J Biol Chem. 2002 Dec 13;277(50):49071-6
pubmed: 12377775